ProKidney Corp. (PROK) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
ProKidney Corp. stock (PROK) is currently trading at $1.79. ProKidney Corp. PS ratio (Price-to-Sales) is 654.41. Analyst consensus price target for PROK is $6.25. WallStSmart rates PROK as Sell.
- PROK PE ratio analysis and historical PE chart
- PROK PS ratio (Price-to-Sales) history and trend
- PROK intrinsic value — DCF, Graham Number, EPV models
- PROK stock price prediction 2025 2026 2027 2028 2029 2030
- PROK fair value vs current price
- PROK insider transactions and insider buying
- Is PROK undervalued or overvalued?
- ProKidney Corp. financial analysis — revenue, earnings, cash flow
- PROK Piotroski F-Score and Altman Z-Score
- PROK analyst price target and Smart Rating
ProKidney Corp.
📊 No data available
Try selecting a different time range
Smart Analysis
ProKidney Corp. (PROK) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
ProKidney Corp. (PROK) Key Strengths (1)
Revenue surging 196.10% year-over-year
Supporting Valuation Data
ProKidney Corp. (PROK) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Very expensive at 654.4x annual revenue
Very expensive at 97.2x book value
Small-cap company with higher risk but more growth potential
Moderate institutional interest at 34.49%
Supporting Valuation Data
ProKidney Corp. (PROK) Detailed Analysis Report
Overall Assessment
This company scores 23/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 2.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 196.10%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (654.41), Price/Book (97.15) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -43.20%, Operating Margin at -20306.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -43.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 196.10% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PROK Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PROK's Price-to-Sales ratio of 654.41x trades 26% below its historical average of 882.54x (0th percentile). The current valuation is 34% below its historical high of 994.69x set in Mar 2026, and 0% above its historical low of 654.41x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~905.7x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for ProKidney Corp. (PROK) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
ProKidney Corp. is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 893,000 with 196% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 196% YoY, reaching 893,000. This pace significantly outperforms most BIOTECHNOLOGY peers.
Debt-to-equity ratio of -0.00 indicates a conservative balance sheet with 95M in cash.
Free cash flow is -38M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can ProKidney Corp. maintain 196%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.80, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact ProKidney Corp..
Bottom Line
ProKidney Corp. is a high-conviction growth story with revenue accelerating at 196% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About ProKidney Corp.(PROK)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
ProKidney Corporation. The company is headquartered in Winston-Salem, North Carolina.